| Primary |
| Product Used For Unknown Indication |
61.8% |
| Lung Disorder |
11.8% |
| Diabetic Foot |
5.9% |
| Device Related Infection |
2.9% |
| Meningioma |
2.9% |
| Osteitis |
2.9% |
| Radioisotope Scan |
2.9% |
| Septic Shock |
2.9% |
| Staphylococcal Infection |
2.9% |
| Wrong Drug Administered |
2.9% |
|
| Red Man Syndrome |
16.7% |
| Thrombocytopenia |
16.7% |
| Epistaxis |
8.3% |
| Hepatocellular Injury |
8.3% |
| Incorrect Dose Administered |
8.3% |
| Influenza Like Illness |
8.3% |
| Pruritus |
8.3% |
| Rash |
8.3% |
| Splenic Vein Thrombosis |
8.3% |
| Wrong Drug Administered |
8.3% |
|
| Secondary |
| Product Used For Unknown Indication |
46.3% |
| Drug Use For Unknown Indication |
6.6% |
| Anaesthesia |
6.4% |
| Adult T-cell Lymphoma/leukaemia |
3.9% |
| Lung Disorder |
3.7% |
| Pneumonia |
3.4% |
| Drug Exposure During Pregnancy |
2.9% |
| Acute Myeloid Leukaemia |
2.6% |
| Infection |
2.6% |
| Pain |
2.6% |
| Endocarditis |
2.4% |
| Osteomyelitis |
2.4% |
| Pyrexia |
2.3% |
| Septic Shock |
2.1% |
| Osteitis |
1.9% |
| Antibiotic Therapy |
1.8% |
| Sepsis |
1.8% |
| Diffuse Large B-cell Lymphoma |
1.6% |
| Chemotherapy |
1.4% |
| Pleural Fistula |
1.4% |
|
| Drug Reaction With Eosinophilia And Systemic Symptoms |
13.0% |
| Renal Failure Acute |
11.0% |
| Thrombocytopenia |
10.0% |
| Pneumonia |
7.0% |
| Toxic Skin Eruption |
7.0% |
| Hepatocellular Injury |
6.0% |
| Skin Exfoliation |
5.0% |
| Skin Test Negative |
5.0% |
| Epistaxis |
4.0% |
| Renal Tubular Necrosis |
4.0% |
| Urticaria |
4.0% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.0% |
| Pruritus |
3.0% |
| Rash Maculo-papular |
3.0% |
| Renal Failure |
3.0% |
| Transaminases Increased |
3.0% |
| Vasculitis |
3.0% |
| Acquired Haemophilia |
2.0% |
| Agranulocytosis |
2.0% |
| Condition Aggravated |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
43.9% |
| Drug Use For Unknown Indication |
10.0% |
| Haemodynamic Instability |
4.0% |
| Viral Infection |
4.0% |
| Convulsion |
3.4% |
| Grand Mal Convulsion |
3.3% |
| Rhabdomyosarcoma |
3.3% |
| Status Epilepticus |
3.3% |
| Burkitt's Lymphoma |
2.9% |
| Prophylaxis |
2.5% |
| Pyrexia |
2.5% |
| Bone Graft |
2.2% |
| Osteitis |
2.2% |
| Hypertension |
2.0% |
| Prophylaxis Against Graft Versus Host Disease |
2.0% |
| Infection |
1.8% |
| Nosocomial Infection |
1.8% |
| Hyperthermia |
1.6% |
| Neoplasm Malignant |
1.6% |
| Plasma Cell Myeloma |
1.6% |
|
| Thrombocytopenia |
13.0% |
| Toxic Epidermal Necrolysis |
9.3% |
| Confusional State |
7.4% |
| Cholestasis |
5.6% |
| Pleural Effusion |
5.6% |
| Respiratory Failure |
5.6% |
| Sepsis |
5.6% |
| Septic Shock |
5.6% |
| Toxic Skin Eruption |
5.6% |
| Hypotension |
3.7% |
| Liver Disorder |
3.7% |
| Mucosal Inflammation |
3.7% |
| Pneumonia |
3.7% |
| Rash Maculo-papular |
3.7% |
| Renal Disorder |
3.7% |
| Renal Failure |
3.7% |
| Renal Failure Acute |
3.7% |
| Somnolence |
3.7% |
| Cerebral Haemorrhage |
1.9% |
| Cerebrovascular Accident |
1.9% |
|
| Interacting |
| Antibiotic Prophylaxis |
100.0% |
|
| Renal Failure Acute |
100.0% |
|
